Researchers have made a major advance in treating people with a severe form of vasculitis, anti-neutrophil cytoplasmic antibody-associated vasculitis, a rare but devastating disease of blood vessels. In a six-month study, a new treatment strategy provided the same benefits as the current standard of care used for more than 40 years but required less frequent treatments.